GlassScriptPhysician profile
Michael Klele
NPI 1861512030
$4,078.11
in general payments reported to CMS, 2019-2025
33 companies · $70.86 in 2025
The $70.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $1,113 · 2021: $828 · 2022: $626 · 2023: $290 · 2025: $70.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,049.44 | 2019-2023 | Breztri, Farxiga, Lokelma |
| Novo Nordisk INC | $491.13 | 2019-2023 | Wegovy |
| Allergan, INC. | $407.88 | 2019-2020 | |
| Abbvie INC. | $267.12 | 2021-2023 | |
| Amarin Pharma, INC. | $241.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $230.85 | 2019-2023 | Arexvy |
| Lilly USA, LLC | $222.42 | 2019-2025 | Zepbound |
| Merck Sharp & Dohme LLC | $105.55 | 2019-2020 | |
| Pfizer INC. | $105.12 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.23 | 2022 | |
| Jazz Pharmaceuticals INC. | $94.17 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $90.55 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $73.45 | 2019-2022 | |
| Amgen INC. | $72.47 | 2021-2025 | Repatha |
| Genentech USA, INC. | $69.14 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.63 | 2019-2022 | |
| Alk-Abello, INC | $51.74 | 2019 | |
| Abbott Laboratories | $41.18 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.66 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $39.78 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.71 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $28.31 | 2022 | |
| Eisai INC. | $26.38 | 2021 | |
| Qiagen, LLC | $17.72 | 2021 | |
| Dermira, INC. | $15.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.87 | 2021 | |
| Astellas Pharma US INC | $14.37 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.11 | 2019 | |
| Bausch Health US, LLC | $13.79 | 2022 | |
| Shire North American Group INC | $12.94 | 2019 | |
| Indivior INC. | $12.19 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Klele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.